SSP 086 for Latanoprost/Timolol eye drops is active 19 Dec 2025–6 Feb 2026. Guidance for pharmacists on substitution and patient care.

SSP 085 for Nifedipine 60mg tablets is active from 19 Dec 2025 to 6 Feb 2026. Guidance for pharmacists on substitution and patient care.

Serious Shortage Protocol for nifedipine (Adipine® XL) 30mg MR tablets in effect from 19 Dec 2025 to 6 Feb 2026. Full guidance for pharmacists.

This Circular advises Health Boards and community pharmacy contractors that four UK-wide Serious Shortage Protocols (SSPs) for Estradot® (estradiol) transdermal patches, 

This Circular advises Health Boards and community pharmacy contractors that two UK-wide Serious Shortage Protocols (SSPs) for Creon® gastro-resistant capsules both due to expire on 21 November 2025 have been extended until Friday 16 January 2026. 

SSP for cefalexin oral suspension sugar free products extended to 28 November 2025. Pharmacists should review updated guidance.

SSPs for Estradot HRT patches extended to 5 Dec 2025. Pharmacists may substitute with Evorel or Estraderm MX. Review updated guidance.

Serious Shortage Protocols for cefalexin oral suspension sugar free products extended to 24 Oct 2025. Applies to SSP077 and SSP078. Review updated guidance.

SSPs for Estradot® HRT patches now end 10 Oct 2025. Pharmacists may substitute with Evorel® or Estraderm MX® to manage supply issues.

A Serious Shortage Protocol (SSP 083) is in effect from 23 June to 1 August 2025 for venlafaxine 37.5mg MR tablets, allowing substitution with capsules. Learn how pharmacists should manage this temporary supply issue.

SSPs for Estradot® HRT patches extended to 10 Oct 2025. Community pharmacy contractors are advised to note the updated expiry date.

SSPs for Estradot® and Creon® extended. Pharmacists advised of new expiry dates: 6 June 2025 for Estradot®, 21 Nov 2025 for Creon® capsules.

This Circular advises community pharmacy contractors that the four UK-wide Serious Shortage Protocols (SSPs) for Estradot® (estradiol) transdermal patches, a hormone replacement therapy (HRT) product, due to expire on 2 May 2025 have been extended.

This Circular advises community pharmacy contractors that the Serious Shortage Protocol for Estradot® (Estradiol) 50 micrograms / 24 hours transdermal patch (SSP079), a hormone replacement therapy (HRT) product, due to expire on 21 March 2025 has been extended until Friday 4 April 2025.

This Circular advises community pharmacy contractors that the Serious Shortage Protocol (SSP) for Ramipril 2.5mg tablets due to expire on 15 November 2024 has been extended until Friday 29 November 2024.

This Circular advises community pharmacy contractors that the Serious Shortage Protocol for isosorbide mononitrate (Monomax® XL) 60mg modified release tablet due to expire on 18 October 2024 has been extended until Friday 15 November 2024. 

To advise of a Serious Shortage Protocol (SSP) in place for isosorbide mononitrate (Chemydur® 60XL) modified release tablet, from 6 September 2024 to 27 September 2024. 

To advise of a Serious Shortage Protocol (SSP) in place for cefalexin 500mg tablets, from 6 August 2024 to 27 September 2024.

To advise of a Serious Shortage Protocol (SSP) in place for ramipril 2.5mg tablets, from 6 August 2024 to 15 November 2024.

This Circular advises Health Boards and community pharmacy contractors that the two UK-wide Serious Shortage Protocols (SSPs) for Clarithromycin 125mg/5ml and 250mg/5ml oral suspension have been reactivated on 22 May 2024. The new end date for both SSPs is now 21 June 2024.